Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.

BMC Cancer · 2025 · PMC12512831 · PMID 41073967

Europe PMC DOI

hedged sentences

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

a favorable trendp = 0.098so close (0.05 < p ≤ 0.1)

HSCT in CR1 was associated with significantly improved OS in intermediate-risk patients ( p = 0.003), showed a favorable trend in adverse-risk patients ( p = 0.098), and conferred no OS benefit in favorable-risk patients ( p = 0.351).

also in 1,335 other papers

showed a trendp = 0.098so close (0.05 < p ≤ 0.1)

In patients achieving first CR, allogeneic hematopoietic stem cell transplantation (HSCT) improved OS in intermediate-risk ( p = 0.003), showed a trend in adverse-risk ( p = 0.098), and no benefit in favorable-risk ( p = 0.351).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.